| Title: | Evaluating the impact of AMPK activation, a target of metformin, on risk of cardiovascular diseases and cancer in the UK Biobank: a Mendelian randomisation study |
| Journal: | Diabetologia |
| Published: | 1 Nov 2020 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/32748028/ |
| DOI: | https://doi.org/10.1007/s00125-020-05243-z |
Publication 3396
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Using Mendelian randomization, our study suggests that activation of adenosine monophosphate-activated protein kinase (AMPK), one of the targets of metformin, may reduce type 2 diabetes, coronary artery disease and overall cancer risk. Whether metformin can be repurposed for the prevention of these diseases should be further explored. We believe the study may generate some discussion in the scientific communities as metformin's anti-cancer property has been controversial.1 Author
- Luo S et al.
1 Application
| Application ID | Title |
|---|---|
| 51001 | Using Mendelian randomization to infer health effects of cardiovascular and diabetes medication in the UK Biobank |
Enabling scientific discoveries that improve human health